EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer

Toshiki Oka iD, Koji Hatano iD, Shohei Katsuki, Tomohiro Kanaki, Shunsuke Inoguchi, Masaru Tani iD, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Yohei Okuda, Akinaru Yamamoto iD und 15 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Toshiki Oka und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiation-Sensitizing Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) from AMED, Japanese Urological Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiation therapy effectively treats prostate cancer, but tumor recurrence remains a clinical challenge, highlighting the need for strategies to enhance radiosensitivity. In this study, we developed a simple, high‐throughput drug repurposing screening platform to find radiosensitizers from compounds approved by the U.S. Food and Drug Administration. A library of 1134 compounds was systematically screened at two concentrations (0.2 and 2 μM) using LNCaP cells stably expressing Metridia luciferase, allowing highly sensitive and quantitative assessment of cell viability through luciferase activity in culture supernatants. In the primary screening, 8 and 12 candidate radiosensitizers were identified at 0.2 μM and 2 μM, respectively. In the secondary screening, 19 compounds were evaluated at two radiation doses (4 Gy and 6 Gy) and six drug concentrations, identifying 5 radiation‐sensitizing candidate compounds. Through this stepwise screening approach, cladribine was identified as the most potent radiosensitizer. Cladribine increased radiation‐induced cytotoxicity in multiple prostate cancer cell lines (22Rv1, DU145, and PC3), with dose‐modifying factors of 1.46, 1.55, and 1.43, respectively, based on the radiation dose needed to achieve 90% cell death. Mechanistically, cladribine prevented the repair of radiation‐induced DNA double‐strand breaks, shown by increased γH2AX levels. Importantly, its radiosensitizing effect was further confirmed in vivo using 22Rv1 and DU145 xenograft models. This study demonstrates that a luciferase‐based high‐throughput drug repurposing platform is useful for identifying clinically relevant radiosensitizers, revealing that cladribine is a promising candidate for further translational research in prostate cancer radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiation-Sensitizing AgentsMaleHumansAnimalsCell Line, TumorMiceHigh-Throughput Screening AssaysCell SurvivalXenograft Model Antitumor AssaysDrug Repositioning

Stichwörter der Autor:innen

cladribinecompound library screeningprostate cancerradiationradiosensitizer

Substanzen

Radiation-Sensitizing Agents

Autor:innen und Institutionen

  • Department of Urology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
  • Department of Medical Physics and Engineering, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
  • Department of Radiation Oncology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
  • Center for Supporting Drug Discovery and Life Science Research, The University of Osaka Graduate School of Pharmaceutical Science, Suita, Osaka, Japan.
  • The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University Schoolof Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Toshiki Oka, Koji Hatano, Masaru Tani, Akinaru Yamamoto, Taigo Kato, Atsunari Kawashima, Norio Nonomura

Förderung

  • Japan Society for the Promotion of Science
  • Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) from AMED
  • Japanese Urological Association

Zitieren

APA

Oka, T., Hatano, K., Katsuki, S., Kanaki, T., Inoguchi, S., Tani, M., Yoshimura, A., Horibe, Y., Liu, Y., Sassi, N., Okuda, Y., Yamamoto, A., Uemura, T., Yamamichi, G., Ishizuya, Y., Hayashi, T., Yamamoto, Y., Kato, T., Kawashima, A., …, & Nonomura, N. (2026). Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer. Cancer Science. https://doi.org/10.1111/cas.70326

Vancouver

Oka T, Hatano K, Katsuki S, Kanaki T, Inoguchi S, Tani M, et al. Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer. Cancer Science. 2026. doi:10.1111/cas.70326

BibTeX
@article{Oka2026,
  author = {Oka, Toshiki and Hatano, Koji and Katsuki, Shohei and Kanaki, Tomohiro and Inoguchi, Shunsuke and Tani, Masaru and Yoshimura, Akihiro and Horibe, Yuki and Liu, Yutong and Sassi, Nesrine and Okuda, Yohei and Yamamoto, Akinaru and Uemura, Toshihiro and Yamamichi, Gaku and Ishizuya, Yu and Hayashi, Takuji and Yamamoto, Yoshiyuki and Kato, Taigo and Kawashima, Atsunari and Tamari, Keisuke and Lin, Bangzhong and Tani, Akiyoshi and Tsujikawa, Kazutake and Takahashi, Yutaka and Ogawa, Kazuhiko and Lupold, Shawn E and Nonomura, Norio},
  title = {Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70326}
}
Kostenlos starten →